Skip to main content
. 2011 Jan;7(1 Suppl 1):4–16.

Table 4.

Efficacy of Boceprevir (BOC) Plus Peginterferon (PEG) and Ribavirin (RBV) in Genotype 1 Patients Who Were Previous Peginterferon and Ribavirin Nonresponders or Relapsers

BOC (44 weeks) + PEG/RBV (48 weeks) (n=161) BOC (RGT) + PEG/RBV (n=162) PEG/RBV (48 weeks) (n=80)
End of therapy response 77% 70% 31%
SVR

  • All patients

 67% (107/161) 59% (95/162) 21% (17/80)

  • Previous nonresponders

 52% (30/58) 40% (23/57) 7% (2/29)

  • Previous relapsers

 75% (77/103) 69% (72/105) 29% (15/51)

  • Patients with null response at Week 4

 34% (15/44) 33% (15/46) 0% (0/12)

  • Patients with non-null response at Week 4

 80% (90/114) 73% (80/110) 26% (17/66)
Relapse rate 12% 15% 32%
RGT

response-guided therapy

SVR

sustained virologic response.